TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Income Tax Expense (Benefit) in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q2 2024.
  • Teva Pharmaceutical Industries Ltd Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $630M.
  • Teva Pharmaceutical Industries Ltd Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $606M, a 174% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Income Tax Expense (Benefit) for 2023 was -$7M, a 98.9% increase from 2022.
  • Teva Pharmaceutical Industries Ltd annual Income Tax Expense (Benefit) for 2022 was -$643M, a 405% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Income Tax Expense (Benefit) for 2021 was $211M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $606M $630M +$646M Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 -$40M -$52M -$33M -174% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$7M $40M -$109M -73.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 $102M -$12M -$119M -111% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-12
Q2 2023 $221M -$16M +$884M +98.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 -$663M -$19M -$21M -1050% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$642M $149M +$174M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$816M $107M +$31M +40.8% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-12
Q2 2022 -$847M -$900M -$998M -1018% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-12
Q1 2022 $151M $2M -$60M -96.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $211M -$25M -$4M -19% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $215M $76M +$60M +375% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $155M $98M +$202M Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$47M $62M +$121M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$168M -$21M +$98M +82.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 -$266M $16M +$5M +45.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 -$271M -$104M +$75M +41.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$346M -$59M -$68M -756% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$278M -$119M +$20M +14.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 -$298M $11M +$37M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$335M -$179M -$103M -136% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$232M $9M -$37M -80.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$195M -$139M +$1.33B +90.6% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 -$1.53B -$26M +$468M +94.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$2B -$76M -$54M -245% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$1.94B $46M -$8M -14.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$1.93B -$1.47B -$1.53B -2681% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 -$405M -$494M -$701M -339% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $296M -$22M -$51M -176% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $347M $54M -$174M -76.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $521M $57M -$192M -77.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $713M $207M +$14M +7.25% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $699M $29M -$59M -67% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $758M $228M +$124M +119% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $634M $249M +$63M +33.9% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $571M $193M +$33M +20.6% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $538M $88M -$14M -13.7% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $552M $104M -$39M -27.3% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $591M $186M +$72M +63.2% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $519M $160M +$148M +1233% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $371M $102M +$324M Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $47M $143M +$90M +170% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 -$43M $114M +$224M Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 -$267M $12M +$69M Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 -$336M -$222M -$261M -669% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 -$75M $53M +$62M Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 -$137M -$110M -$128M -711% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 -$9M -$57M -$90M -273% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $81M $39M +$12M +44.4% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $69M -$9M -$58M -118% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $127M $18M +$71M Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $56M $33M -$100M -75.2% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $156M $27M -$91M -77.1% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $247M $49M -$36M -42.4% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $283M -$53M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $133M Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $118M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $85M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.